Gene study aims to personalize prostate cancer care

NCT ID NCT02705846

First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 29 times

Summary

This study follows over 4,000 men with prostate cancer, some with rare gene mutations (BRCA1, BRCA2, HOXB13, Lynch Syndrome) and some without. Researchers will track their treatment results and survival over time. The goal is to learn whether these mutations affect how the disease progresses, which could help tailor future treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institute of Cancer Research and Royal Marsden Hospital

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could guide doctors on the best prostate cancer treatments for men with specific gene mutations, potentially improving survival.

What could go wrong

This is an observational study, not a treatment trial. It will not directly benefit participants and may take years to yield clear guidance.

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.